SecurityCMD / Cantel Medical Corp
CEOKrakauer Andrew A
IndustrySurgical and Medical Instruments and Apparatus
Institutional Owners0
Common Stock Shares Outstanding41,709,335 shares (as of 2018-04-30)
Related CMN / Cantel Medical Corp.

Institutional Stock Ownership and Shareholders

Cantel Medical Corp (NYSE:CMD) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Cantel Medical Corp (NYSE:CMD) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

6h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

Related News Stories

Micron (MU) Q4 Earnings and Revenues Surpass Estimates

2018-09-20 zacks
Micron (MU - Free Report) came out with quarterly earnings of $3.53 per share, beating the Zacks Consensus Estimate of $3.32 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring items. (1-0)

United Natural Foods (UNFI) Misses Q4 Earnings and Revenue Estimates

2018-09-20 zacks
United Natural Foods (UNFI - Free Report) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items. (5-0)

Cantel Medical (CMD) Q4 Earnings Preview: What's Shaping Up?

2018-09-20 zacks
Wall Street expects a year-over-year increase in earnings on higher revenues when Cantel Medical (CMD - Free Report) reports results for the quarter ended July 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

Bulletproof Investing Performance Update, Week 42

2018-09-18 seekingalpha
It has been six months since I presented four hedged portfolios and 10 top names in week 42 of my Marketplace service (March 15). Here's how everything did. (10-0)

Bulletproof Investing Performance Update: Week 38

2018-08-16 seekingalpha
It's been six months since I presented 4 hedged portfolios and 10 top names in week 38 of my Marketplace service (February 15th). Here's how everything did. (11-0)

Motus Could Get Knocked When Lockup Expires

2018-08-07 seekingalpha
When MOTS' 180 lockup period expires on August 13th, pre-IPO shareholders and company insiders will be able to sell more than 10 million currently-restricted shares. (3-2)

20 Massively Underpriced Stocks Wall Street Expects to Soar

2018-06-25 investorplace
Wall Street doesn’t always get it right, but analysts’ track record is better than some skeptics suggest. And when the Street as a whole is arguing for big upside, investors should at least consider what those analysts have to say. (982-14)

Buy Cantel Medical, A High Quality Growth Story

2018-06-18 seekingalpha
Cantel Medical (CMD) is a high quality growth company that is likely to significantly grow its earnings over the next 5 years. The company supplies a diverse set of very stable and growing medical end-markets. The company has a strong track record of generating organic growth but has also demonstrated an ability to grow inorganically through bolt-on acquisitions. (20-0)

New And Old Investing Stories To Be Told

2018-06-01 seekingalpha
This week's Editor's Notes covers a few ideas on the long side that tend to appeal to value investors - the insurance company, the holding company, international growth. (53-0)

Cantel Medical Corporation (CMD) CEO Jorgen Hansen on Q3 2018 Results - Earnings Call Transcript

2018-05-31 seekingalpha
Greetings and welcome to the Cantel Medical Corp Third Quarter 2018 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Milicent Brooks, Head of Corporate Communications at Cantel Medical. Thank you, Ms. Brooks. You may begin. (8-1)